CoChat

Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study

Open access
Wang, William, Volkow, Nora D., Berger, Nathan A., Davis, Pamela B., Kaelber, David C., Xu, Rong · 2024 · Molecular Psychiatry
Cited by 83

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Cannabis is the most frequently used illicit drug in the United States with more than 45 million users of whom one-third suffer from a cannabis use disorder (CUD). Despite its high prevalence, there are currently no FDA-approved medications for CUD. Patients treated with semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA) approved for treating type 2 diabetes (T2D) and for weight management have reported reduced desire to drink and smoke. Preclinical studies have shown that semaglutide decreased nicotine and alcohol consumption. Preclinical and preliminary clinical evidence of semaglutide’s potential beneficial effects on various substance use disorders led us to evaluate if it pertained to CUD. In this retrospective cohort study of electronic health records (EHRs) from the TriNetX Analytics Network, a global federated health research network of approximately 105.3 million patients from 61 large healthcare organizations in the US, we aimed to assess the associations of semaglutide with both incident and recurrent CUD diagnosis compared to non-GLP-1RA anti-obesity or anti-diabetes medications. Hazard ratio (HR) and 95% confidence intervals (CI) of incident and recurrent CUD were calculated for 12-month follow-up by comparing propensity-score matched patient cohorts. The study population included 85,223 patients with obesity who were prescribed semaglutide or non-GLP-1RA anti-obesity medications, with the findings replicated in 596,045 patients with T2D. In patients with obesity (mean age 51.3 years, 65.6% women), semaglutide compared with non-GLP-1RA anti-obesity medications was associated with lower risk for incident CUD in patients with no prior history CUD (HR: 0.56, 95% CI: 0.42–0.75), and recurrent CUD diagnosis in patients with a prior history CUD (HR: 0.62, 95% CI: 0.46–0.84). Consistent reductions were seen for patients stratified by gender, age group, race and in patients with and without T2D. Similar findings were replicated in the study population with T2D when comparing semaglutide with non-GLP-1RA anti-diabetes medications for incident CUD (HR: 0.40, 95% CI: 0.29–0.56) and recurrent CUD (HR: 0.66, 95% CI: 0.42–1.03). While these findings provide preliminary evidence of the potential benefit of semaglutide in CUD in real-world populations, further preclinical studies are warranted to understand the underlying mechanism and randomized clinical trials are needed to support its use clinically for CUD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41380-024-02498-5

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Research works printed but not linked: 36

  1. Chandra S, Radwan MM, Majumdar CG, Church JC, Freeman TP, ElSohly MA. New trends in cannabis potency in USA and Europe during the last decade (2008-2017). Eur Arch Psychiatry Clin Neurosci. 2019;269:5–15. · DOI · Paper page
  2. Fontanella CA, Steelesmith DL, Brock G, Bridge JA, Campo JV, Fristad MA Association of Cannabis Use With Self-harm and Mortality Risk Among Youths With Mood Disorders. JAMA Pediatr. 2021. https://doi.org/10.1001/jamapediatrics.2020.5494. · DOI
  3. Kung H-C, Pearson JL, Liu X. Risk factors for male and female suicide decedents ages 15-64 in the United States. Results from the 1993 National Mortality Followback Survey. Soc Psychiatry Psychiatr Epidemiol. 2003;38:419–26. · DOI
  4. Arendt M, Munk-Jørgensen P, Sher L, Jensen SOW. Mortality following treatment for cannabis use disorders: predictors and causes. J Subst Abus Treat. 2013;44:400–6. · DOI
  5. Evans B, Stoltzfus B, Acharya N, Nyland JE, Arnold AC, Freet CS, et al. Dose titration with the glucagon-like peptide-1 agonist, liraglutide, reduces cue- and drug-induced heroin seeking in high drug-taking rats. Brain Res Bull. 2022;189:163–73. · DOI
  6. Wang L, Wang Q, Davis PB, Volkow ND, Xu R. Increased risk for COVID‐19 breakthrough infection in fully vaccinated patients with substance use disorders in the United States between December 2020 and August 2021. World Psychiatry. 2022;21:124–32. · DOI · Paper page
  7. Wang L, Berger NA, Kaelber DC, Davis PB, Volkow ND, Xu R Incidence Rates and Clinical Outcomes of SARS-CoV-2 Infection With the Omicron and Delta Variants in Children Younger Than 5 Years in the US. JAMA Pediatr. 2022. https://doi.org/10.1001/jamapediatrics.2022.0945. · DOI · Paper page
  8. Wang L, Davis PB, Kaelber DC, Volkow ND, Xu R Comparison of mRNA-1273 and BNT162b2 Vaccines on Breakthrough SARS-CoV-2 Infections, Hospitalizations, and Death During the Delta-Predominant Period. JAMA. 2022. https://doi.org/10.1001/jama.2022.0210. · DOI · Paper page
  9. Wang L, Davis PB, Kaelber DC, Xu R COVID-19 breakthrough infections and hospitalizations among vaccinated patients with dementia in the United States between December 2020 and August 2021. Alzheimers Dement. 2022. https://doi.org/10.1002/alz.12669. · DOI · Paper page
  10. Wang W, Kaelber DC, Xu R, Berger NA. Breakthrough SARS-CoV-2 Infections, Hospitalizations, and Mortality in Vaccinated Patients With Cancer in the US Between December 2020 and November 2021. JAMA Oncol. 2022;8:2022 https://doi.org/10.1001/jamaoncol.2022.1096. · DOI · Paper page
  11. Wang L, Kaelber DC, Xu R, Berger NA. COVID-19 breakthrough infections, hospitalizations and mortality in fully vaccinated patients with hematologic malignancies: A clarion call for maintaining mitigation and ramping-up research. Blood Rev. 2022;54:100931. · DOI · Paper page
  12. Wang L, Berger NA, Xu R. Risks of SARS-CoV-2 Breakthrough Infection and Hospitalization in Fully Vaccinated Patients With Multiple Myeloma. JAMA Netw Open. 2021;4:e2137575. · DOI · Paper page
  13. Wang L, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R Association of COVID-19 with endocarditis in patients with cocaine or opioid use disorders in the US. Mol Psychiatry. 2022. https://doi.org/10.1038/s41380-022-01903-1. · DOI
  14. Gao Z, Winhusen TJ, Gorenflo M, Ghitza UE, Davis PB, Kaelber DC, et al. Repurposing ketamine to treat cocaine use disorder: integration of artificial intelligence-based prediction, expert evaluation, clinical corroboration and mechanism of action analyses. Addiction. 2023. https://doi.org/10.1111/add.16168. · DOI · Paper page
  15. Olaker VR, Kendall EK, Wang CX, Parran TV, Terebuh P, Kaelber DC, et al. Association of recent SARS-CoV-2 infection with new-onset alcohol use disorder, January 2020 through January 2022. JAMA Netw Open. 2023;6:e2255496. · DOI
  16. Wang L, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R. Cardiac and mortality outcome differences between methadone, buprenorphine and naltrexone prescriptions in patients with an opioid use disorder. J Clin Psychol. 2023;79:2869–83. · DOI
  17. Wang L, Davis PB, Volkow ND, Berger NA, Kaelber DC, Xu R. Association of COVID-19 with new-onset Alzheimer’s disease. J Alzheimers Dis. 2022. https://doi.org/10.3233/JAD-220717. · DOI · Paper page
  18. Wang L, Wang W, Kaelber DC, Xu R, Berger NA. GLP-1 Receptor Agonists and Colorectal Cancer Risk in Drug-Naive Patients With Type 2 Diabetes, With and Without Overweight/Obesity. JAMA Oncol. 2023. https://doi.org/10.1001/jamaoncol.2023.5573. · DOI
  19. Hernán MA, Robins JM. Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available. Am J Epidemiol. 2016;183:758–64. · DOI · Paper page
  20. Dugas EN, Sylvestre M-P, Ewusi-Boisvert E, Chaiton M, Montreuil A, O’Loughlin J. Early Risk Factors for Daily Cannabis Use in Young Adults. Can J Psychiatry. 2019;64:329–37. · DOI
  21. van den Bree MBM, Pickworth WB. Risk factors predicting changes in marijuana involvement in teenagers. Arch Gen Psychiatry. 2005;62:311–9. · DOI · Paper page
  22. Brezing CA, Levin FR. The Current State of Pharmacological Treatments for Cannabis Use Disorder and Withdrawal. Neuropsychopharmacology. 2018;43:173–94. · DOI
  23. Sabioni P, Le Foll B. Psychosocial and pharmacological interventions for the treatment of cannabis use disorder. Focus (Am Psychiatr Publ). 2019;17:163–8.
  24. Leung J, Chan GCK, Hides L, Hall WD. What is the prevalence and risk of cannabis use disorders among people who use cannabis? a systematic review and meta-analysis. Addict Behav. 2020;109:106479. · DOI · Paper page
  25. Robinson T, Ali MU, Easterbrook B, Coronado-Montoya S, Daldegan-Bueno D, Hall W, et al. Identifying risk-thresholds for the association between frequency of cannabis use and development of cannabis use disorder: A systematic review and meta-analysis. Drug Alcohol Depend. 2022;238:109582. · DOI
  26. Berger AL, Henricks AM, Lugo JM, Wright HR, Warrick CR, Sticht MA, et al. The lateral habenula directs coping styles under conditions of stress via recruitment of the endocannabinoid system. Biol Psychiatry. 2018;84:611–23. · DOI
  27. Rashidy-Pour A, Pahlevani P, Vaziri A, Shaigani P, Zarepour L, Vafaei AA, et al. Involvement of CB1 receptors in the ventral tegmental area in the potentiation of morphine rewarding properties in acquisition but not expression in the conditioned place preference model. Behav Brain Res. 2013;247:259–67. · DOI
  28. French ED, Dillon K, Wu X. Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra. Neuroreport. 1997;8:649–52. · DOI · Paper page
  29. French ED. Δ9-Tetrahydrocannabinol excites rat VTA dopamine neurons through activation of cannabinoid CB1 but not opioid receptors. Neurosci Lett. 1997;226:159–62. · DOI · Paper page
  30. Massi L, Elezgarai I, Puente N, Reguero L, Grandes P, Manzoni OJ, et al. Cannabinoid receptors in the bed nucleus of the stria terminalis control cortical excitation of midbrain dopamine cells in vivo. J Neurosci. 2008;28:10496–508. · DOI
  31. Zheng H, Reiner DJ, Hayes MR, Rinaman L. Chronic suppression of glucagon-like peptide-1 receptor (GLP1R) mRNA translation in the rat bed nucleus of the stria terminalis reduces anxiety-like behavior and stress-induced hypophagia, but prolongs stress-induced elevation of plasma corticosterone. J Neurosci. 2019;39:2649–63. · DOI · Paper page
  32. Zizzari P, He R, Falk S, Bellocchio L, Allard C, Clark S, et al. CB1 and GLP-1 receptors cross talk provides new therapies for obesity. Diabetes. 2021;70:415–22. · DOI
  33. González-Mariscal I, Krzysik-Walker SM, Kim W, Rouse M, Egan JM. Blockade of cannabinoid 1 receptor improves GLP-1R mediated insulin secretion in mice. Mol Cell Endocrinol. 2016;423:1–10. · DOI
  34. Moss CE, Marsh WJ, Parker HE, Ogunnowo-Bada E, Riches CH, Habib AM, et al. Somatostatin receptor 5 and cannabinoid receptor 1 activation inhibit secretion of glucose-dependent insulinotropic polypeptide from intestinal K cells in rodents. Diabetologia. 2012;55:3094–103. · DOI · Paper page
  35. Patel KN, Joharapurkar AA, Patel V, Kshirsagar SG, Bahekar R, Srivastava BK, et al. Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice. Can J Physiol Pharm. 2014;92:975–83. · DOI
  36. Radziszewska E, Bojanowska E. Effects of glucagon-like peptide-1 receptor stimulation and blockade on food consumption and body weight in rats treated with a cannabinoid CB1 receptor agonist WIN 55,212-2. Med Sci Monit Basic Res. 2013;19:6–11. · DOI

Cited by

See all 83

Metadata

Authors
Wang, W., Volkow, N. D., Berger, N. A., Davis, P. B., Kaelber, D. C., & Xu, R.
Venue
Molecular Psychiatry
Published
2024-03-14
Volume
29
Issue
8
Pages
2587-2598
ISSN
  • 1359-4184 (ISSN-L)
  • 1476-5578
OpenAlex
W4392817429
Cited by
83
References
15
FWCI
19.56
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study. https://app.cochat.ai/papers/10.1038/s41380-024-02498-5
The paper
Wang, W., Volkow, N. D., Berger, N. A., Davis, P. B., Kaelber, D. C., & Xu, R. (2024). Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study. Molecular Psychiatry. https://doi.org/10.1038/s41380-024-02498-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.